[ad_1]
The vaccination program in Austria will continue with the AstraZeneca vaccine.
© AP
The National Vaccination Committee (NIG) has again discussed the AstraZeneca corona vaccine and recommended that the vaccination program continue in Austria.
The situation of blood clots (thrombosis) in relation to vaccines is currently being evaluated in an ongoing procedure by the European Medicines Agency (EMA), it said in a statement. However, to date, the available data has not yet produced a homogeneous picture.
Association with blood clots: more data will be analyzed
Data is continuously collected and analyzed from both the EU and Austria and Great Britain. In the week after Easter, at a PRAC / EMA meeting, all international data available up to that point should be examined, according to the NIG Safety Board statement. A statement from the EMA on AstraZeneca’s COVID-19 vaccine is then expected.
In Germany, the federal and state governments decided Tuesday to administer the AstraZeneca vaccine only to people 60 and older. The background for this is the cases of blood clots (thrombosis) in the cerebral veins in connection with vaccines. The director of the NIG, Ursula Wiedermann-Schmidt, spoke in the evening at the “ZiB2” against the ban on vaccination in Austria. It is important to maintain the risk-benefit ratio.
AstraZeneca welcomes Austria’s decision
AstraZeneca welcomed Austria’s decision. “I am very pleased with the NIG’s decision and that Austria will continue to use AstraZeneca’s COVID-19 vaccine to protect people from this deadly virus. Patient safety remains our top priority. The NIG’s decision is in line with the Conclusions from the EU and WHO regulatory authorities: The benefits of the AstraZeneca COVID-19 vaccine still far outweigh the potential risks in all age groups, “said Sarah Walters, National President of AstraZeneca Austria.
Read all about corona vaccination in our special
[ad_2]
